Etohi1 inhibitors are a specialized class of chemical compounds designed to specifically target and inhibit the function of the Etohi1 protein, which is involved in a range of cellular processes. Etohi1 is a member of a larger family of enzymes known for their role in regulating various intracellular activities, including the modulation of signaling pathways and protein interactions. Inhibitors of Etohi1 function by binding to the active site or an allosteric site on the protein, thereby obstructing its normal function. This binding is often achieved through the formation of a non-covalent or covalent complex, which effectively reduces or abolishes the enzyme's activity. The development of Etohi1 inhibitors typically involves a combination of high-throughput screening, computational modeling, and structure-based drug design to identify and optimize molecules with high specificity and affinity for the target enzyme.
The structural diversity of Etohi1 inhibitors reflects the complexity of the enzyme's active site and the need for precise molecular interactions to achieve effective inhibition. These inhibitors often contain a variety of functional groups that can engage in multiple types of interactions with the protein, such as hydrogen bonding, van der Waals forces, and hydrophobic interactions. Additionally, the design of these inhibitors takes into consideration the enzyme's conformational flexibility, which can influence how inhibitors bind and modulate enzyme activity. Advanced techniques like X-ray crystallography, NMR spectroscopy, and molecular docking are frequently employed to study the binding interactions at an atomic level, providing insights that guide the refinement of inhibitor design. The goal in developing Etohi1 inhibitors is to create compounds that are not only potent but also selective for Etohi1, reducing the likelihood of cross-reactivity with other proteins in the same family. This specificity is crucial for understanding the precise role of Etohi1 in cellular processes and for studying its biochemical pathways in detail.
SEE ALSO...
Items 11 to 12 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
GSK 650394 | 890842-28-1 | sc-361201 sc-361201A | 10 mg 50 mg | $187.00 $769.00 | 8 | |
GSK-650394 activates Etohi1 by inhibiting p38 MAP kinase. Its suppression of p38 MAP kinase signaling may lead to Etohi1 activation and modulation of cellular processes associated with Etohi1. | ||||||
3,3′-Diindolylmethane | 1968-05-4 | sc-204624 sc-204624A sc-204624B sc-204624C sc-204624D sc-204624E | 100 mg 500 mg 5 g 10 g 50 g 1 g | $37.00 $65.00 $89.00 $421.00 $681.00 $66.00 | 8 | |
DIM activates Etohi1 by modulating the PI3K/Akt pathway. Its impact on PI3K/Akt signaling may lead to Etohi1 activation and modulation of cellular processes associated with Etohi1. | ||||||